About 17 million people suffer a stroke each year globally, more than all dementias combined, including Alzheimer’s. Only 1 in 10 currently receive treatment, and only about 1 in 10 of those ever return to life as it was before. The socioeconomic consequences are enormous – stroke is the second leading cause of death globally and the leading cause of neurological disability. The need is urgent for therapies that are neuroprotective in the acute phase and promote neuroplasticity in the recovery phase. The recent string of positive endovascular thrombectomy trials has validated patient selection criteria, novel clinical trial models have made the studies in both acute and chronic patients feasible, and emerging therapies in late stage development have returned neuroprotection to the forefront of CNS drug development.
Ability Level: All
Session ID: 503739